Vera Therapeutics (VERA) AI Stock Analysis

• Market Cap: $3.39B
• Dividend Yield: N/A
• Average Volume (3M): 1.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: N/A
• EPS Growth: -53.44%
• Country: US
• Employees: 152
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.26
• Shares Outstanding: 70,066,180
• 10 Day Avg. Volume: 1,120,971
• 30 Day Avg. Volume: 1,474,393
• PEG Ratio: -0.69
• Price to Book (P/B): 4.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.25
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -908.25
• Enterprise Value/Ebitda: -4.21
• 1Y Price Target: $74.08
• Price Target Upside: 53.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $54.00 ▲(11.55% Upside)

The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), despite a supportive balance sheet. Technicals are a clear positive with strong trend and momentum, while valuation remains challenged due to ongoing losses and no dividend. Recent corporate events add a constructive tailwind via Phase 3 results and fresh capital, tempered by executive turnover.

Positive Factors

Strong Equity Position

A strong equity position with low debt leverage indicates prudent financial management, providing stability and flexibility for future growth.

Innovative Product Pipeline

The focus on innovative therapies for unmet needs in immunological diseases positions Vera Therapeutics as a potential leader in biotechnology, supporting long-term growth.

Significant Partnerships

Partnerships with industry leaders enhance research capabilities and provide potential revenue streams, strengthening Vera's market position and growth prospects.

Negative Factors

Consistent Net Losses

Ongoing net losses and negative EBIT margins highlight financial instability, which could hinder investment in R&D and long-term growth.

Negative Cash Flows

Negative cash flows indicate cash management challenges, potentially limiting operational flexibility and increasing reliance on external financing.

Lack of Revenue Growth

Lack of revenue growth amidst rising losses suggests difficulty in scaling operations, which may impact long-term viability and competitiveness.

Vera Therapeutics Business Overview & Revenue Model

Company Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

How the Company Makes Money

Vera Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes licensing agreements, research collaborations, and eventually, sales of approved therapies. Key revenue streams involve upfront payments, milestone payments, and royalties from commercial partnerships with larger pharmaceutical companies. Significant partnerships with industry leaders and research organizations play a crucial role in advancing their drug development programs and contributing to potential future earnings.

Vera Therapeutics Financial Statement Overview

Summary

Vera Therapeutics faces financial instability with consistent net losses and negative EBIT margins. Although there is a positive trend in gross profit, cash flow challenges remain due to negative free cash flows and reliance on financing. The balance sheet shows a strong equity position with low debt leverage, but fluctuations in the equity ratio indicate potential asset management volatility.

Income Statement

Vera Therapeutics has faced a challenging period with consistent net losses and negative EBIT margins over the years. The absence of revenue growth and a significant increase in net losses highlight financial instability. However, the improvements in gross profit from negative to positive values in recent years offer a slight positive trajectory.

Balance Sheet

The company demonstrates a strong equity position with a growing stockholders' equity, minimizing debt leverage. The debt-to-equity ratio remains low, indicating prudent financial management. However, the overall equity ratio has fluctuated, reflecting potential volatility in asset management.

Cash Flow

Vera Therapeutics experiences negative free cash flows, with operating cash flow consistently below net income, highlighting cash management challenges. A positive note is the significant financing inflows that bolster cash reserves, although relying on financing isn't sustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.13M	0.00	0.00	846.00K	0.00	-251.00K
EBITDA	-243.18M	-144.42M	-92.18M	-88.91M	-32.41M	-52.99M
Net Income	-251.94M	-152.15M	-95.99M	-89.06M	-32.61M	-53.41M
Balance Sheet
Total Assets	517.50M	655.68M	175.55M	131.44M	83.75M	54.55M
Cash, Cash Equivalents and Short-Term Investments	497.39M	640.85M	160.72M	114.65M	79.67M	53.65M
Total Debt	77.22M	54.64M	53.71M	31.29M	4.92M	2.00K
Total Liabilities	118.62M	78.53M	73.86M	54.53M	14.16M	143.90M
Stockholders Equity	398.88M	577.15M	101.69M	76.91M	69.59M	-89.35M
Cash Flow
Free Cash Flow	-211.47M	-135.65M	-92.24M	-67.66M	-23.71M	-34.91M
Operating Cash Flow	-210.29M	-134.68M	-92.18M	-67.60M	-23.71M	-34.81M
Investing Cash Flow	-107.76M	-425.03M	-39.43M	-70.55M	-4.20M	-42.00K
Financing Cash Flow	348.57M	606.67M	133.54M	101.93M	53.88M	85.29M

Vera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.41
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERA, the sentiment is Positive. The current price of 48.41 is below the 20-day moving average (MA) of 49.90, above the 50-day MA of 40.28, and above the 200-day MA of 28.01, indicating a neutral trend. The MACD of 1.69 indicates Positive momentum. The RSI at 54.48 is Neutral, neither overbought nor oversold. The STOCH value of 47.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VERA.

Vera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	60 Neutral	$3.22B	-9.56	-47.40%	―	23340.07%	18.06%
VERA	56 Neutral	$3.39B	-12.14	-73.25%	―	―	-53.44%
PHVS	56 Neutral	$1.64B	-7.96	-51.81%	―	―	-20.08%
EWTX	55 Neutral	$2.98B	-17.86	-30.02%	―	―	-5.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JANX	48 Neutral	$849.29M	-8.43	-12.48%	―	-23.37%	-42.45%
BHVN	48 Neutral	$1.70B	-1.54	-522.08%	―	―	18.76%

Vera Therapeutics Corporate Events

Vera Therapeutics Announces Departure of Chief Legal Officer

On December 16, 2025, Vera Therapeutics, Inc. announced that Jason Carter will step down from his role as Chief Legal Officer, effective December 24, 2025. The leadership change removes a key executive from the company’s legal function and may signal an upcoming transition or reorganization within its senior management team.

The most recent analyst rating on (VERA) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.

Vera Therapeutics Completes Successful Stock Offering

On December 9, 2025, Vera Therapeutics, Inc. announced a follow-on public offering of 6,138,108 shares of its Class A common stock at a price of $42.50 per share, expected to generate approximately $260.9 million in gross proceeds. The offering, set to close on December 11, 2025, includes an option for underwriters to purchase an additional 920,716 shares, which was fully exercised on December 10, 2025. This move is part of Vera Therapeutics’ strategy to strengthen its financial position and potentially expand its market presence, with implications for stakeholders depending on market conditions and other external factors.

The most recent analyst rating on (VERA) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.

Vera Therapeutics Appoints James R. Meyers to Board

On November 25, 2025, Vera Therapeutics, Inc. appointed James R. Meyers to its board as a Class II Director, with his term expiring at the 2026 Annual Meeting of Stockholders. Meyers will also serve on the Audit Committee and has been granted a stock option to purchase 25,000 shares, with additional compensation including a pro-rated annual cash retainer for 2025. This appointment is part of Vera Therapeutics’ strategy to strengthen its board with experienced leadership, potentially impacting its governance and operational oversight positively.

The most recent analyst rating on (VERA) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.

Vera Therapeutics Announces Promising Phase 3 Trial Results

On November 6, 2025, Vera Therapeutics announced significant results from its ORIGIN Phase 3 trial of atacicept for IgA nephropathy, presented at the American Society of Nephrology Kidney Week and published in The New England Journal of Medicine. The trial showed a 46% reduction in proteinuria and favorable safety outcomes, positioning atacicept as a promising treatment option and potentially impacting the company’s market position positively.

The most recent analyst rating on (VERA) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.